A Phase 1/2 interventional study of Pembrolizumab and PegIFN-2b in Renal Cell Carcinoma and Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing pembrolizumab in Carcinoma, Renal Cell — 17 open to participants now, 23 under way, 4 of them phase 3. pembrolizumab · Carcinoma, Renal Cell.
Among the 48 studies testing pembrolizumab in Carcinoma, Renal Cell, this one is the 8th largest by enrollment, is one of 3 that started in 2014, is one of 3 in phase 1/2, and was the 2nd registered.
2,041 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.
Browse Carcinoma, Renal Cell studies →17 of the 48 studies testing pembrolizumab in Carcinoma, Renal Cell are open now, in 8 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
Giuseppe Procopio · Sites in Italy
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 33 · Phase 3 6 · Phase 4 1
First in 2013; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 295 is above the median of 43 across 1,567 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 41 across the 48 interventional studies. Of the 17 that completed or were terminated, 11 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 48 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
33 studies in Carcinoma, Renal Cell by Merck & Co., Inc: 3 open now, 15 under way, 7 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 33 studies in Carcinoma, Renal Cell by Merck & Co., Inc, this one is the 10th largest by enrollment, is one of 3 that started in 2014, is one of 6 in phase 1/2, and was the 7th registered.
Merck & Co., Inc’s Carcinoma, Renal Cell studies by the year they started, since 2007.
3 of the studies testing pembrolizumab in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05319015University of Texas Southwestern Medical CenterNeoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus | 2026-12 |
| NCT07187778M.D. Anderson Cancer CenterPhase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) | 2027-07-19 |
| NCT06302569Giuseppe ProcopioPembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 48 studies testing pembrolizumab in Carcinoma, Renal Cell, from their registry updates:
Among Merck & Co., Inc’s 33 in Carcinoma, Renal Cell:
This tab as a report to print or save as PDF → With an account.
This study is being done to analyze the safety, tolerability, and efficacy of treatment for advanced melanoma (MEL) and renal cell carcinoma (RCC) using combination regimens of pembrolizumab + pegylated interferon alfa-2b (PegIFN-2b) and pembrolizumab + ipilimumab (IPI). The primary hypothesis is that these combinations will be sufficiently well-tolerated to permit continued clinical investigation.
The trial is being done in three parts: Part 1A (MEL and RCC) will define the maximum tolerated dose (MTD)/maximum administered dose (MAD) for the drug combinations; a recommended Phase 2 dose (RP2D) for each combination will be identified. Part 1B (MEL-single arm expansion) will better characterize safety and efficacy and provide preliminary efficacy data for the pembrolizumab + IPI combination in participants with MEL. Part 1C (MEL) is added as the third part of the study with Amendment 3. Part 1C will evaluate safety and efficacy for different doses and dosing intervals for IPI in combination with pembrolizumab in participants with advanced MEL.
In the pembrolizumab + IPI study arms, qualified participants who receive the first course but experience disease progression after discontinuing pembrolizumab with stable disease or better, may, at the investigator's discretion, initiate a second course of pembrolizumab at the same dose and schedule for up to 17 doses (up to \~1 additional year) + IPI at the same dose and schedule for up to 4 doses (up to \~12 additional weeks). In the pembrolizumab + PEG-IFN study arms, qualified participants who receive the first course but experience disease progression after discontinuing pembrolizumab with stable disease or better may, at the investigator's discretion, initiate a second course of pembrolizumab at the same dose and schedule for up to 17 doses (up to \~1 additional year). Per protocol, response or progression during the second course will not count towards efficacy outcome measure and adverse events during the second course will not count towards safety outcome measures.
Part 2 (MEL and RCC) is a randomized portion of the trial and will evaluate preliminary efficacy of the drug combinations for advanced MEL participants. Part 2 was removed from the study with Amendment 3 of the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Part 1A receive pembrolizumab intravenously (IV) 200 mg every three weeks (Q3W) + PEG-IFN at assigned dose subcutaneously (SC) once a week for up to \~2 years.
Biological: Pembrolizumab · Biological: PegIFN-2b
Participants in Parts 1A and 1B receive pembrolizumab IV 200 mg Q3W for up to \~2 years + IPI IV 1 mg/kg Q3W for up to \~12 weeks.
Biological: Pembrolizumab · Biological: Ipilimumab
Participants in Part 1C receive pembrolizumab IV 200 mg Q3W for up to \~2 years + IPI IV 50 mg every 6 weeks (Q6W) for up to \~24 weeks.
Biological: Pembrolizumab · Biological: Ipilimumab
Participants in Part 1C receive pembrolizumab IV 200 mg Q3W for up to \~2 years + IPI IV 100 mg every 12 weeks (Q12W) for up to \~48 weeks.
Biological: Pembrolizumab · Biological: Ipilimumab
IV infusion
Also known as: KEYTRUDA®, MK-3475
Subcutaneous infusion
Also known as: PegIntron®, Sylatron®
IV infusion
Also known as: Yervoy®
Percentage of Participants With Dose-limiting Toxicities (DLTs) (Part 1A)
Participants in Part 1A were analyzed for DLTs. DLTs included all adverse experiences that were clearly not related to disease progression or intercurrent illness if judged by the investigator to be possibly, probably, or definitely related to study intervention. Reported adverse experiences used the Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.0. DLTs were analyzed and reported separately for protocol specified clinical indications of metastatic melanoma (MEL) and renal cell carcinoma (RCC) in Part 1A: Part 1A Pembrolizumab + IPI 1mg/kg (MEL), Part 1A Pembrolizumab + IPI 1 mg/kg (RCC), Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (MEL), Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (RCC), Part 1A Pembrolizumab + PEG-IFN 2 µg/kg (RCC). Per protocol, DLT outcome analysis did not include Parts 1B and 1C.
Time frame: Up to ~6 Weeks
Percentage of Participants Experiencing Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0.The number of participants who experienced at least one AE was reported.
Time frame: Up to ~84 months
Percentage of Participants Discontinuing Study Drug Due to AEs
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the CTCAE Version 4.0. The percentage of participants who discontinued study treatment due to an AE was reported.
Time frame: Up to ~24 months
Percentage of Participants Experiencing Adverse Events of Special Interest (AEOSIs) (Parts 1B and 1C)
AEOSIs consist of immune-mediated events, infusion reactions and depression. Events include Pneumonitis, Colitis, Hepatitis, Nephritis, Adrenal Insufficiency, Hypophysitis, Hyperthyroidism, Hypothyroidism, Thyroiditis, Type 1 Diabetes Mellitus, Skin Disorders, Uveitis, Pancreatitis, Myositis, Guillain-Barre Syndrome, Myocarditis, Encephalitis, Sarcoidosis, Infusion Reactions, Myasthenic Syndrome, Myelitis, Vasculitis, and Cholangitis Sclerosing. Per protocol Part 1B and Part 1C are reported. Part 1A was not included in the AEOIs outcome analysis, per protocol.
Time frame: Up to ~84 months
Percentage of Participants Experiencing Grade 3-5 Drug-related AEs (Part 1C)
Participants in Part 1C who experienced grade 3-5 drug-related AEs (DRAEs) using CTCAE Version 4.0 are presented. Grade 3-5 DRAEs for Parts 1A and 1B was a secondary outcome analysis, per protocol and reported later in the record.
Time frame: Up to ~84 months
Objective Response Rate (ORR) (Part 1C)
ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experienced a CR or PR is presented. Per protocol, ORR in Part 1C was planned and conducted as a pre-specified primary outcome analysis. ORR in Part 1B was planned and conducted as a protocol-specified secondary outcome analysis and has been reported later in the record. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.
Time frame: Up to ~84 months
Progression-free Survival (PFS) (Part 2)
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was to be assessed by independent central review per RECIST 1.1. Part 2 of the study was not conducted, based on protocol specified criteria and this Part 2 specific outcome measure could not be reported.
Time frame: Up to ~84 months
Objective Response Rate (ORR) (Part 1B)
ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Per protocol, ORR in Part 1B was planned and conducted as a pre-specified secondary outcome analysis. ORR in Part 1C was planned and conducted as a protocol-specified primary outcome analysis and has been reported earlier in the record. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.
Time frame: Up to ~84 months
ORR by Programmed-death Receptor-ligand 1 (PD-L1) Status Using RECIST 1.1 (Parts 1B and 1C)
ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of participants that experienced a CR or PR by PD-L1 status is presented. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. ORR for participants in Parts 1B and 1C with measurable disease at baseline based on central independent review, who had ORR data available for PD-L1+ and PD-L1- participants are presented. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.
Time frame: Up to ~84 months
Percentage of Participants With an Ordinal Response, Estimated by a Best Overall Response of VGPR or MPR (Parts 1B and 1C)
Ordinal response, per RECIST 1.1 included the best overall responses of Very Good Partial Response (\[VGPR\]\>60% tumor reduction) as well as Moderate Partial Response (\[MPR\]\>30%- ≤60% tumor reduction). The percentage of participants in Part 1B and 1C who experienced a MPR or VGPR (based on the degree of tumor shrinkage) in participants with advanced melanoma is presented. Outcome analysis of ordinal response in Part 1A was not planned or conducted in this study, per protocol.
Time frame: Up to ~84 months
Duration of Response (DOR) (Parts 1B and 1C)
DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on central imaging review with confirmation. The DOR as assessed using RECIST 1.1 for participants with measurable disease at baseline based on central independent review in Parts 1B and 1C who experienced a confirmed CR or PR with DOR data available is presented. Outcome analysis of DOR in Part 1A was not planned or conducted in this study, per protocol.
Time frame: Up to ~84 months
Progression-free Survival (PFS) (Parts 1B and 1C)
PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by independent central review per RECIST 1.1 for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had PFS data available is presented. Outcome analysis of PFS in Part 1A was not planned or conducted in this study, per protocol.
Time frame: Up to ~84 months
Overall Survival (OS) (Parts 1B and 1C)
OS was defined as the time from randomization to death due to any cause. OS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had OS data available is presented. Outcome analysis of OS in Part 1A was not planned or conducted in this study, per protocol.
Time frame: Up to ~84 months
PFS by PD-L1 Status Using RECIST 1.1 (Parts 1B and 1C)
PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. PFS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had PFS data available for PD-L1+ and PD-L1- participants is presented. Outcome analysis of PFS in Part 1A was not planned or conducted in this study, per protocol.
Time frame: Up to ~84 months
OS by PD-L1 Status Using RECIST 1.1 (Parts 1B and 1C)
OS was defined as the time from randomization to death due to any cause. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. OS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had OS data available for PD-L1+ and PD-L1- participants is presented. Outcome analysis of OS in Part 1A was not planned or conducted in this study, per protocol.
Time frame: Up to ~84 months
Percentage of Participants Experiencing Grade 3-5 DRAEs (Parts 1A and 1B)
Participants in Parts 1A and 1B who experienced DRAEs using CTCAE Version 4.0 are presented. Grade 3-5 DRAEs for Part 1C was a primary outcome analysis, per protocol and reported earlier in the record.
Time frame: Up to ~84 months
ORR (Part 2)
ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. Part 2 of the study was not conducted, based on protocol specified criteria and this Part 2 specific outcome measure was not reported.
Time frame: Up to ~84 months
| Milestone | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + Pegylated Interferon Alfa-2b (PEG-IFN) 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab + IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| Started | 23 | 14 | 3 | 153 | 51 | 51 |
| Treated | 22 | 14 | 3 | 153 | 51 | 51 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 23 | 14 | 3 | 153 | 51 | 51 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Clinical progression | 4 | 0 | 0 | 5 | 1 | 2 |
| Withdrew: Excluded medication | 1 | 0 | 0 | 11 | 2 | 1 |
| Withdrew: Progressive disease | 13 | 10 | 3 | 51 | 17 | 12 |
| Withdrew: Follow up ended by sponsor | 2 | 2 | 0 | 70 | 26 | 26 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 8 | 1 | 1 |
| Withdrew: Status not recorded | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 7 | 2 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Screen failure | 1 | 0 | 0 | 0 | 0 | 0 |
Participants in Part 1A were analyzed for DLTs. DLTs included all adverse experiences that were clearly not related to disease progression or intercurrent illness if judged by the investigator to be possibly, probably, or definitely related to study intervention. Reported adverse experiences used the Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.0. DLTs were analyzed and reported separately for protocol specified clinical indications of metastatic melanoma (MEL) and renal cell carcinoma (RCC) in Part 1A: Part 1A Pembrolizumab + IPI 1mg/kg (MEL), Part 1A Pembrolizumab + IPI 1 mg/kg (RCC), Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (MEL), Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (RCC), Part 1A Pembrolizumab + PEG-IFN 2 µg/kg (RCC). Per protocol, DLT outcome analysis did not include Parts 1B and 1C.
| Percentage of Participants | Part 1A Pembrolizumab + IPI 1 mg/kg (MEL) | Part 1A Pembrolizumab + IPI 1 mg/kg (RCC) | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (MEL) | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (RCC) | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg (RCC) | Part 1B Pembrolizumab+ IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Dose-limiting Toxicities (DLTs) (Part 1A) | 36.4 (20.6 to 54.5) | 25 (10.2 to 45.4) | 20 (5.1 to 44.8) | 0.0 (0.0 to 14.9) | 66.7 (36.5 to 89.4) | — | — | — |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0.The number of participants who experienced at least one AE was reported.
| Percentage of Participants | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab+ IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing Adverse Events (AEs) | 100.0 | 100.0 | 100.0 | 99.3 | 100.0 | 100.0 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the CTCAE Version 4.0. The percentage of participants who discontinued study treatment due to an AE was reported.
| Percentage of Participants | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab+ IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Discontinuing Study Drug Due to AEs | 40.9 | 50.0 | 66.7 | 37.3 | 19.6 | 37.3 |
AEOSIs consist of immune-mediated events, infusion reactions and depression. Events include Pneumonitis, Colitis, Hepatitis, Nephritis, Adrenal Insufficiency, Hypophysitis, Hyperthyroidism, Hypothyroidism, Thyroiditis, Type 1 Diabetes Mellitus, Skin Disorders, Uveitis, Pancreatitis, Myositis, Guillain-Barre Syndrome, Myocarditis, Encephalitis, Sarcoidosis, Infusion Reactions, Myasthenic Syndrome, Myelitis, Vasculitis, and Cholangitis Sclerosing. Per protocol Part 1B and Part 1C are reported. Part 1A was not included in the AEOIs outcome analysis, per protocol.
| Percentage of Participants | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab+ IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing Adverse Events of Special Interest (AEOSIs) (Parts 1B and 1C) | — | — | — | 60.8 | 45.1 | 56.9 |
Participants in Part 1C who experienced grade 3-5 drug-related AEs (DRAEs) using CTCAE Version 4.0 are presented. Grade 3-5 DRAEs for Parts 1A and 1B was a secondary outcome analysis, per protocol and reported later in the record.
| Percentage of Participants | Part 1A Pembrolizumab + IPI 1mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab+ IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing Grade 3-5 Drug-related AEs (Part 1C) | — | — | — | — | 27.5 | 43.1 |
ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experienced a CR or PR is presented. Per protocol, ORR in Part 1C was planned and conducted as a pre-specified primary outcome analysis. ORR in Part 1B was planned and conducted as a protocol-specified secondary outcome analysis and has been reported later in the record. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.
| Percentage of Participants | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab+ IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) (Part 1C) | — | — | — | — | 69.6 (54.2 to 82.3) | 76.7 (61.4 to 88.2) |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was to be assessed by independent central review per RECIST 1.1. Part 2 of the study was not conducted, based on protocol specified criteria and this Part 2 specific outcome measure could not be reported.
No measurements were reported for this outcome.
ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Per protocol, ORR in Part 1B was planned and conducted as a pre-specified secondary outcome analysis. ORR in Part 1C was planned and conducted as a protocol-specified primary outcome analysis and has been reported earlier in the record. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.
| Percentage of Participants | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab+ IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) (Part 1B) | — | — | — | 65.8 (57.5 to 73.4) | — | — |
ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of participants that experienced a CR or PR by PD-L1 status is presented. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. ORR for participants in Parts 1B and 1C with measurable disease at baseline based on central independent review, who had ORR data available for PD-L1+ and PD-L1- participants are presented. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.
| Percentage of Participants | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab+ IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| PD-L1 Positive | — | — | — | 67.8 (58.7 to 76.0) | 75.0 (55.1 to 89.3) | 85.2 (66.3 to 95.8) |
| PD-L1 Negative | — | — | — | 52.2 (30.6 to 73.2) | 53.8 (25.1 to 80.8) | 63.6 (30.8 to 89.1) |
Ordinal response, per RECIST 1.1 included the best overall responses of Very Good Partial Response (\[VGPR\]\>60% tumor reduction) as well as Moderate Partial Response (\[MPR\]\>30%- ≤60% tumor reduction). The percentage of participants in Part 1B and 1C who experienced a MPR or VGPR (based on the degree of tumor shrinkage) in participants with advanced melanoma is presented. Outcome analysis of ordinal response in Part 1A was not planned or conducted in this study, per protocol.
| Percentage of Participants | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab+ IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| MPR | — | — | — | 6.2 (2.9 to 11.4) | 8.7 (2.4 to 20.8) | 23.3 (11.8 to 38.6) |
| VGPR | — | — | — | 24.0 (17.3 to 31.7) | 28.3 (16.0 to 43.5) | 20.9 (10.0 to 36.0) |
DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on central imaging review with confirmation. The DOR as assessed using RECIST 1.1 for participants with measurable disease at baseline based on central independent review in Parts 1B and 1C who experienced a confirmed CR or PR with DOR data available is presented. Outcome analysis of DOR in Part 1A was not planned or conducted in this study, per protocol.
| Months | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab+ IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| Duration of Response (DOR) (Parts 1B and 1C) | — | — | — | NA (NA to NA) | NA (NA to NA) | NA (3.8 to NA) |
PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by independent central review per RECIST 1.1 for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had PFS data available is presented. Outcome analysis of PFS in Part 1A was not planned or conducted in this study, per protocol.
| Months | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab+ IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) (Parts 1B and 1C) | — | — | — | NA (36.4 to NA) | NA (14.1 to NA) | NA (31.9 to NA) |
OS was defined as the time from randomization to death due to any cause. OS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had OS data available is presented. Outcome analysis of OS in Part 1A was not planned or conducted in this study, per protocol.
| Months | Part 1A Pembrolizumab + IPI 1mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab + IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| Overall Survival (OS) (Parts 1B and 1C) | — | — | — | NA (NA to NA) | NA (NA to NA) | NA (39.6 to NA) |
PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. PFS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had PFS data available for PD-L1+ and PD-L1- participants is presented. Outcome analysis of PFS in Part 1A was not planned or conducted in this study, per protocol.
| Months | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab + IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| PD-L1 Positive | — | — | — | NA (41.6 to NA) | NA (NA to NA) | NA (35.7 to NA) |
| PD-L1 Negative | — | — | — | 20.7 (2.8 to NA) | 23.1 (1.4 to NA) | 13.8 (1.4 to NA) |
OS was defined as the time from randomization to death due to any cause. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. OS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had OS data available for PD-L1+ and PD-L1- participants is presented. Outcome analysis of OS in Part 1A was not planned or conducted in this study, per protocol.
| Months | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab + IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| PD-L1 Positive | — | — | — | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| PD-L1 Negative | — | — | — | NA (14.1 to NA) | 32.8 (12.9 to NA) | NA (7.6 to NA) |
Participants in Parts 1A and 1B who experienced DRAEs using CTCAE Version 4.0 are presented. Grade 3-5 DRAEs for Part 1C was a primary outcome analysis, per protocol and reported earlier in the record.
| Percentage of Participants | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab + IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing Grade 3-5 DRAEs (Parts 1A and 1B) | 90.9 | 71.4 | 66.7 | 70.6 | — | — |
ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. Part 2 of the study was not conducted, based on protocol specified criteria and this Part 2 specific outcome measure was not reported.
No measurements were reported for this outcome.
Collected over Up to approximately 84 months (through database cutoff date of 01-April-2021).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1A Pembrolizumab + IPI 1 mg/kg | 16/23 (69.6%) | 9/22 (40.9%) | 22/22 (100%) |
| Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | 10/14 (71.4%) | 9/14 (64.3%) | 14/14 (100%) |
| Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 1B Pembrolizumab + IPI 1 mg/kg | 51/153 (33.3%) | 78/153 (51%) | 152/153 (99.3%) |
| Part 1C Pembrolizumab + IPI 50 mg | 14/51 (27.5%) | 26/51 (51%) | 51/51 (100%) |
| Part 1C Pembrolizumab + IPI 100 mg | 17/51 (33.3%) | 25/51 (49%) | 51/51 (100%) |
| Event | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab + IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| DepressionPsychiatric disorders | 0/22 | 1/14 | 1/3 | 1/153 | 0/51 | 0/51 |
| Suicide attemptPsychiatric disorders | 0/22 | 0/14 | 1/3 | 0/153 | 0/51 | 0/51 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/22 | 1/14 | 1/3 | 4/153 | 1/51 | 2/51 |
| ColitisGastrointestinal disorders | 3/22 | 0/14 | 0/3 | 6/153 | 2/51 | 2/51 |
| Atrial fibrillationCardiac disorders | 0/22 | 1/14 | 0/3 | 3/153 | 0/51 | 0/51 |
| Autoimmune thyroiditisEndocrine disorders | 0/22 | 1/14 | 0/3 | 0/153 | 0/51 | 0/51 |
| DiarrhoeaGastrointestinal disorders | 0/22 | 1/14 | 0/3 | 2/153 | 0/51 | 0/51 |
| NauseaGastrointestinal disorders | 0/22 | 1/14 | 0/3 | 0/153 | 0/51 | 1/51 |
| VomitingGastrointestinal disorders | 0/22 | 1/14 | 0/3 | 0/153 | 0/51 | 0/51 |
| PyrexiaGeneral disorders | 0/22 | 1/14 | 0/3 | 1/153 | 1/51 | 1/51 |
| Event | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + PEG-IFN 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab + IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg |
|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 9/22 | 11/14 | 3/3 | 89/153 | 31/51 | 34/51 |
| DiarrhoeaGastrointestinal disorders | 6/22 | 5/14 | 2/3 | 60/153 | 23/51 | 24/51 |
| ChillsGeneral disorders | 2/22 | 5/14 | 2/3 | 11/153 | 6/51 | 0/51 |
| PyrexiaGeneral disorders | 5/22 | 5/14 | 2/3 | 20/153 | 7/51 | 3/51 |
| Alanine aminotransferase increasedInvestigations | 5/22 | 3/14 | 2/3 | 24/153 | 10/51 | 6/51 |
| Aspartate aminotransferase increasedInvestigations | 4/22 | 4/14 | 2/3 | 20/153 | 10/51 | 7/51 |
| DepressionPsychiatric disorders | 1/22 | 1/14 | 2/3 | 6/153 | 0/51 | 2/51 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/22 | 9/14 | 2/3 | 38/153 | 17/51 | 11/51 |
| PruritusSkin and subcutaneous tissue disorders | 3/22 | 5/14 | 2/3 | 71/153 | 19/51 | 30/51 |
| RashSkin and subcutaneous tissue disorders | 4/22 | 5/14 | 2/3 | 73/153 | 27/51 | 24/51 |
| Age, Continuous(Years) | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + Pegylated Interferon Alfa-2b (PEG-IFN) 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab + IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 59.4 ± 12.3 | 60.3 ± 10.4 | 61.7 ± 18.5 | 59.9 ± 12.5 | 60.8 ± 12.9 | 62.8 ± 11 | 60.5 ± 12.2 |
| Sex: Female, Male(Participants) | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + Pegylated Interferon Alfa-2b (PEG-IFN) 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab + IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 10 | 5 | 0 | 52 | 13 | 18 | 98 |
| Male | 13 | 9 | 3 | 101 | 38 | 33 | 197 |
| Ethnicity (NIH/OMB)(Participants) | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + Pegylated Interferon Alfa-2b (PEG-IFN) 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab + IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 | 2 | 0 | 4 |
| Not Hispanic or Latino | 21 | 9 | 2 | 142 | 41 | 45 | 260 |
| Unknown or Not Reported | 1 | 5 | 1 | 10 | 8 | 6 | 31 |
| Race (NIH/OMB)(Participants) | Part 1A Pembrolizumab + IPI 1 mg/kg | Part 1A Pembrolizumab + Pegylated Interferon Alfa-2b (PEG-IFN) 1 µg/kg | Part 1A Pembrolizumab + PEG-IFN 2 µg/kg | Part 1B Pembrolizumab + IPI 1 mg/kg | Part 1C Pembrolizumab + IPI 50 mg | Part 1C Pembrolizumab + IPI 100 mg | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 0 | 1 | 1 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| White | 19 | 13 | 1 | 150 | 42 | 46 | 271 |
| More than one race | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Unknown or Not Reported | 2 | 0 | 1 | 0 | 8 | 4 | 15 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2014 to primary completion in Apr 2021, 84 months.
Results were first posted in May 2022, 1 year 1 month after primary completion.
Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 84 months is above that.
Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pembrolizumab · Peginterferon alfa-2b · Ipilimumab